

1 **Supplemental data**

2

3 **Angiotensin IV attenuates diabetic cardiomyopathy *via* suppressing**

4 **FoxO1-induced excessive autophagy, apoptosis and fibrosis**

5 **Short title:** *Ang IV attenuates diabetic cardiomyopathy*

6 **By:**

7 Meng Zhang¹, Wenhai Sui¹, Yanqiu Xing², Jing Cheng³, Cheng Cheng¹, Fei
8 Xue¹, Jie Zhang¹, Xiaohong Wang¹, Cheng Zhang^{1*}, Panpan Hao^{1*}, and Yun
9 Zhang^{1*}

10 **From:**

11 ¹The Key Laboratory of Cardiovascular Remodeling and Function Research,
12 Chinese Ministry of Education, Chinese National Health Commission and
13 Chinese Academy of Medical Sciences, The State and Shandong Province
14 Joint Key Laboratory of Translational Cardiovascular Medicine, Department of
15 Cardiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University,
16 Jinan 250012, Shandong, China.

17 ²Department of Geriatrics, Qilu Hospital, Cheeloo College of Medicine,
18 Shandong University, Key Laboratory of Cardiovascular Proteomics of
19 Shandong Province, Jinan 250012, Shandong, China.

20 ³Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.

21 ***Correspondence:** Yun Zhang, MD, PhD, FACC, FESC, FASE, E-mail:

22 zhangyun@sdu.edu.cn, or Panpan Hao, MD, PhD, E-mail:

23 panda.how@sdu.edu.cn, or Cheng Zhang, MD, PhD, FACC, FESC, E-mail:

- 1 zhangc@sdu.edu.cn, Department of Cardiology, Qilu Hospital, Cheeloo
- 2 College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
- 3

1 **Table S1. Effects of Ang IV on fasting serum lipid and glucose levels and**
 2 **blood pressure in 5 groups of mice of the first part *in vivo* experiment**

	NC	DM	Low-dose Ang IV	Medium-do se Ang IV	High-dose Ang IV
TC (mmol/L)	3.18 ± 0.40	2.48 ± 0.33	2.41 ± 0.24	2.45 ± 0.20	2.38 ± 0.15
LDL-C (mmol/L)	2.14 ± 0.17	1.93 ± 0.14	1.68 ± 0.14	1.94 ± 0.13	1.71 ± 0.12
HDL-C (mmol/L)	0.77 ± 0.10	0.84 ± 0.10	0.57 ± 0.09	0.69 ± 0.12	0.60 ± 0.07
TG (mmol/L)	1.40 ± 0.22	1.19 ± 0.17	0.99 ± 0.09	1.18 ± 0.12	0.93 ± 0.09
GLU (mmol/L)	6.30 ± 1.05	19.42 ± 1.64***	21.63 ± 2.06***	23.23 ± 1.19***	24.21 ± 1.13***
SBP (mmHg)	116.4 ± 3.95	113.8 ± 3.76	115.1 ± 3.76	114.4 ± 3.22	115.2 ± 3.67
MBP (mmHg)	93.24 ± 3.26	94.57 ± 4.11	97.15 ± 4.95	96.02 ± 2.71	88.48 ± 4.06
DBP (mmHg)	84.58 ± 3.68	83.79 ± 3.71	77.64 ± 3.52	83.91 ± 5.90	79.64 ± 5.22

3 Ang IV: angiotensin IV; DBP: diastolic blood pressure; DM: diabetes mellitus;
 4 GLU: glucose; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density
 5 lipoprotein cholesterol; MBP: mean blood pressure; NC: normal control; SBP:
 6 systolic blood pressure; TC: total cholesterol; TG: triglycerides. *** $p < 0.001$ vs.
 7 the NC group. $n \geq 8$ per group.

8

1 **Table S2. Effects of FoxO1 and AT₄R on fasting serum lipid and glucose**
 2 **levels and blood pressure in 5 groups of mice of the second part *in vivo***
 3 **experiment**

	DM	Ang IV	Ang IV+ Divalinal	AS	Ang IV+AS
TC (mmol/L)	2.30 ± 0.25	2.59 ± 0.20	2.29 ± 0.23	2.44 ± 0.14	2.55 ± 0.10
LDL-C (mmol/L)	1.69 ± 0.09	1.86 ± 0.14	1.87 ± 0.15	1.65 ± 0.09	1.84 ± 0.17
HDL-C (mmol/L)	0.80 ± 0.09	0.70 ± 0.06	0.73 ± 0.07	0.60 ± 0.05	0.68 ± 0.06
TG (mmol/L)	1.18 ± 0.10	1.23 ± 0.09	1.36 ± 0.18	1.28 ± 0.09	1.17 ± 0.12
GLU (mmol/L)	22.86 ± 1.12	23.46 ± 1.12	20.99 ± 1.18	22.64 ± 1.40	24.27 ± 1.08
SBP (mmHg)	112.9 ± 4.14	117.3 ± 3.87	115.4 ± 3.28	117.3 ± 3.81	113.0 ± 3.39
MBP (mmHg)	92.36 ± 4.23	90.11 ± 3.87	93.78 ± 4.81	90.21 ± 2.69	87.88 ± 4.02
DBP (mmHg)	79.40 ± 5.03	73.88 ± 5.81	80.80 ± 4.88	75.93 ± 4.90	71.80 ± 3.92

4 Ang IV: angiotensin IV; AS: AS1842856; DBP: diastolic blood pressure; DM:
 5 diabetes mellitus; GLU: glucose; HDL-C: high-density lipoprotein cholesterol;
 6 LDL-C: low-density lipoprotein cholesterol; MBP: mean blood pressure; SBP:
 7 systolic blood pressure; TC: total cholesterol; TG: triglycerides. n ≥ 8 per
 8 group.

9




figure S1


1

2 **Figure S1. Effects of Ang IV, AT₄R and FoxO1 on survival rate in 5 groups**

3 **of mice, respectively. (A)** The Kaplan-Meier survival curves in 5 groups of

4 mice of the first part *in vivo* experiment. **(B)** The Kaplan-Meier survival curves

5 in 5 groups of mice on the second part *in vivo* experiment.



1

2 **Figure S2. Effects of DM and Ang IV on myocardial autophagy in mice.**

3 **(A)** Representative images of MDC labelled particles in the myocardium of NC

4 and DM groups of mice. **(B)** Quantification of MDC labelled particles in the


5 myocardium of NC and DM groups of mice. n=8 per group. **(C)** Representative

6 Western blot images of LC3 and p62 in the NC and DM groups of mice. **(D)**

7 Quantification of LC3-II and p62 expressions in the NC and DM groups of mice.


8 n=8 per group. **(E)** Representative Western blot images of LC3 and p62 in the

1 myocardium of normal mice treated with vehicle or Ang IV. **(F)** Quantification of
 2 LC3-II and p62 expressions in NC and Ang IV groups of normal mice. n=9 per
 3 group. Ang IV: angiotensin IV; DM: diabetes mellitus; NC: normal control. *** p
 4 < 0.001.




5
 6 **Figure S3. Effects of AT₄R and FoxO1 on myocardial fibrosis and**
 7 **apoptosis in 5 groups of mice of the second part *in vivo* experiment. (A)**
 8 **Representative H&E and Masson's trichrome in 5 groups of mice. (B-C)**
 9 **Quantification of collagen volume fraction (CVF) and the ratio of perivascular**
 10 **collagen area to luminal area (PVCA/LA). (D) Representative**
 11 **immunohistochemical staining of Col I, Col III, and TUNEL in 5 groups of mice.**
 12 **(E-G) Quantification of immunohistochemical staining of Col I, Col III, and**
 13 **TUNEL staining. n=5 per group. Ang IV: angiotensin IV; AS: AS1842856; Col I:**

1 collagen I; Col III: collagen III; DM: diabetes mellitus. * $p < 0.05$, ** $p < 0.01$, and
 2 *** $p < 0.001$.



3
 4 **Figure S4. Effects of different concentrations of glucose on expressions**
 5 **of apoptosis- and autophagy-associated proteins in H9C2**
 6 **cardiomyocytes. (A)** Representative Western blot images of LC3, p62, Bax
 7 and Bcl-2 in 5 groups of cells. **(B-D)** Quantification of LC3-II level, p62 level
 8 and Bax/Bcl-2 ratio in 5 groups of cells. n=3 per group. * $p < 0.05$, ** $p < 0.01$,
 9 and *** $p < 0.001$.



1

2 **Figure S5. Effects of Ang IV, AT₄R and FoxO1 on the expressions of**

3 **fibrosis-associated markers in cardiac fibroblasts. (A) Representative**

4 **Western blot images of Col I, Col III, TGF-β1 and FoxO1 in 6 groups of cells.**

1 **(B-E)** Quantification of Col I, Col III, TGF- β 1 and FoxO1 expressions in 6
2 groups of cells. **(F)** Representative Western blot images of Col I, Col III and
3 TGF- β 1 in 7 groups of cells. **(G-I)** Quantification of Col I, Col III and TGF- β 1
4 expressions in 7 groups of cells. n=3 per group. Ang IV: angiotensin IV; AS:
5 AS1842856; Con: normal glucose control; Col I: collagen I; Col III: collagen III;
6 FoxO1-OE: FoxO1 overexpression; HG: high glucose; HO: high osmotic
7 control. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$.

8

9

1 **Materials and methods**

2 **Effects of DM and Ang IV on myocardial autophagy in mice**

3 To examine the effect of DM on myocardial autophagy (Fig. S2A-2D), 24
4 eight-week-old male mice with C57BL/6J background were randomly divided
5 into NC and DM groups (12 mice in each group). DM was induced in mice via
6 intraperitoneal injection of STZ as described in the text. Mice in the NC group
7 were injected with vehicle (0.1 mL of citrate buffer, pH 4.5) instead of STZ.
8 After feeding with a normal chow for 24 weeks, chloroquine (Cq, MCE,
9 HY-17589A, 10 mg/kg) was intraperitoneally injected into the NC and DM mice.
10 Three hours after injection, monodansyl cadaverine (MDC, MCE, HY-D1027,
11 1.5 mg/kg) was intraperitoneally injected into mice. An hour after MDC
12 injection, mice were euthanized and their hearts were harvested. Cryostat
13 sections of the heart were obtained and proteins from the heart were extracted
14 for Western blot analysis.

15 To clarify the effect of Ang IV on myocardial autophagy in normal mice (Fig.
16 S2E-2F), 24 eight-week-old male mice with C57BL/6J background were
17 randomly divided into NC and Ang IV groups (12 mice in each group). Saline or
18 Ang IV (2.88 mg/kg/day) were respectively infused into mice via subcutaneous
19 osmotic mini-pumps for 16 weeks. Then mice were euthanized and their hearts
20 were harvested. Proteins were extracted for Western blot analysis.

21 **Echocardiographic imaging**

22 Transthoracic echocardiography was performed at the end of 24 weeks using

1 the Vevo2100 imaging system (VisualSonics, Toronto, Canada) under 2%
2 isoflurane anesthesia on a heated platform. Left ventricular end-diastolic
3 diameter (LVEDD), and left ventricular ejection fraction (LVEF) and fractional
4 shortening (FS) were measured by M-mode echocardiography in the
5 parasternal long-axis view. The early (E) and late (A) diastolic mitral flow
6 velocities were measured by pulsed Doppler in the apical four-chamber view,
7 and the ratio of E/A was calculated. The early (E') and late (A') diastolic mitral
8 annular velocities were measured by tissue Doppler imaging in the apical
9 four-chamber view, and the ratio of E'/A' was derived.

10 **Blood pressure measurement**

11 Blood pressure was measured by a noninvasive tail-cuff system (Softron
12 BP-98A, Tokyo, Japan) in all mice that were trained first to adapt to the device
13 to ensure reproducible measurements. Blood pressure was measured
14 between 9:00 AM and 11:00 AM by the same operator and recorded as the
15 mean of three consecutive measurements.

16 **Biochemical assay**

17 The serum levels of total cholesterol (TC), low-density lipoprotein cholesterol
18 (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG)
19 were measured in all mice by using a commercial kit (Roche, Mannheim,
20 Germany). The serum level of fasting blood glucose (FBG) was measured
21 using an Accu Chek glucose meter and the matched blood glucose strips
22 (Roche, Mannheim, Germany).

1 **Histological and immunochemical staining**

2 Freshly excised hearts were fixed in 4% paraformaldehyde,
3 paraffin-embedded, and sectioned into 4- μ m thick slices. Hematoxylin and
4 eosin (H&E) staining was performed to display cardiomyocyte morphology.
5 Masson's trichrome staining was used to display collagen deposition. Sections
6 were dewaxed, incubated overnight at 4 °C with corresponding primary
7 antibody against collagen I (Col I; 1:100 dilution), collagen III (Col III; 1:50),
8 microtubule-associated protein 1 light chain 3 β (LC3; 1:100 dilution), Beclin1
9 (1:100) or p62 (1:100; all Abcam, Cambridge, MA), and subsequently
10 incubated with corresponding secondary antibody for 30 min at 37 °C. Then
11 sections were stained with diaminobenzidine and hematoxylin.

12 LC3 was stained with an autophagy kit (KGAF004, KeyGEN, China)
13 following the manufacturer's instructions. In brief, cardiomyocytes were
14 stimulated with indicated agents for 12 h, and chloroquine diphosphate (30 μ M)
15 was added to the medium and incubated for the next 12 h. Thereafter, cells
16 were fixed with 4% paraformaldehyde and stained with LC3 antibody and
17 FITC-labeled secondary antibody. All histological images were analyzed with
18 the Image-Pro Plus 6.0 software.

19 **Transmission electron microscopy**

20 Myocardial tissues were isolated from mice of all groups (n=3 each), fixed with
21 2.5% glutaraldehyde, post-fixed with 1% osmium tetroxide, dehydrated
22 through a graded ethanol series, and embedded in epoxy resin. Ultra-thin

1 sections (90 nm thick) were double-stained with uranyl acetate and lead citrate,
2 and then the images were captured using a transmission electron microscope
3 (H-7000FA, Hitachi, Tokyo, Japan).

4 **Detection and quantitation of apoptosis**

5 Apoptotic cells in tissue sections were detected with a TUNEL detection kit
6 (Roche, Germany) according to the manufacturer's instructions. In brief, slides
7 were de-waxed and incubated with TdT and dUTP mixture for 2 h at 37 °C.
8 Then converter-POD was added to tissues followed by diaminobenzidine and
9 hematoxylin staining.

10 **Microarray protocol**

11 Myocardial tissues were isolated from mice of NC, DM, and DM+high-dose
12 Ang IV groups (n=4) for microarray. Total RNA was extracted using Trizol
13 reagent (Life Technologies, Carlsbad, CA) and purified with an RNeasy mini kit
14 (Qiagen, Valencia, CA). Biotinylated cDNA was prepared according to the
15 standard Affymetrix protocol from 250 ng total RNA. Following labeling,
16 fragmented cDNA was hybridized for 16 h at 45 °C using the Clariom™ S
17 Assay (Affymetrix, Santa Clara, CA). GeneChips were washed and stained in
18 the Affymetrix Fluidics Station 450. All arrays were scanned by using
19 Affymetrix® GeneChip Command Console (AGCC) which was installed in
20 GeneChip® Scanner 3000 7G.

21 Affymetrix GeneChip standard hybridization quality control was
22 bioB<bioC<bioD<cre; neg<pos. The raw data were normalized by the

1 Transcriptome Analysis Console software (version: 4.0.1) with Robust
2 Multichip Analysis (RMA) algorithm using Affymetrix default analysis settings
3 and global scaling as a normalization method. The values presented were \log_2
4 RMA signal intensity and the microarray data are publicly available at NCBI
5 Gene Expression Omnibus (GEO) under accession number GSE157331.

6 In microarrays, we used the limma R package (version: 3.36.5) based on
7 moderated F-statistic to filter the differentially expressed genes (DEGs).
8 Empirical Bayes moderation was used to correct the p values. The
9 Benjamini-Hochberg method was used for multiple test correction (false
10 discovery rate was used to adjust the p values for multiple comparisons). The
11 threshold set for up- and down-regulated genes was fold change > 2.0 , p-value
12 < 0.05 and false discovery rate < 0.05 .

13 Hierarchical clustering was performed based on differentially expressed
14 mRNAs using an R package heatmap (version: 1.0.12). To clarify the biological
15 functions of the genes and the involved signaling pathways, we annotated
16 each gene based on the Gene Ontology (GO) and Kyoto Encyclopedia of
17 Genes and Genomes (KEGG) databases. Enrichment calculations were
18 performed using Fisher's exact test. We further conducted GO and pathway
19 enrichment analysis of the target genes. The specific principle was to carry out
20 annotation mapping of DEGs in GO and KEGG database entries, calculate the
21 number of the target genes in each GO and pathway entry, and then use the
22 hypergeometric test for statistics. The GO and KEGG entries that were

1 significantly enriched in the DEGs were selected. After the calculated p-value
2 was corrected by multiple hypothesis tests, the p-value 0.05 was taken as the
3 threshold, and the GO and KEGG terms meeting this condition were defined
4 as significant enrichment.

5 **Western blot analysis**

6 Proteins of murine hearts and cardiomyocyte extracts were separated by
7 SDS-PAGE and transferred to polyvinylidene fluoride membranes for
8 incubation with primary antibodies against Col I (1:1000 dilution), Col III
9 (1:500), TGF- β 1 (1:1000), Bax (1:1000), Bcl-2 (1:1000), LC3 (1:4000), Beclin1
10 (1:1000), GAPDH (1:1000; all Abcam), SQSTM1/p62 (1:1000), FoxO1
11 (1:1000), pFoxO1 (1:1000) and cleaved caspase 3 (Cl-caspase3; 1:1000) (all
12 CST, Danvers, MA) overnight at 4 °C and appropriate secondary antibodies
13 (1:5000; Proteintech, Wuhan, China) for 1 h at room temperature. Protein
14 levels were normalized to that of GAPDH.

15 **Cytoplasmic and nuclear extraction**

16 The separation experiment of cytoplasmic and nuclear extraction was
17 performed by using Minute™ Cytoplasmic & Nuclear Extraction Kits (Invent,
18 SC-003), following the standard protocol. Briefly, cells were harvested in
19 suspension by low-speed centrifugation (500 g for 3 min), and the supernatant
20 was aspirated completely. Cytoplasmic extraction buffer was added to cell
21 pellets, and the tube was vortexed vigorously for 15 s, incubated on ice for 5
22 min, and then centrifuged for 5 min at top speed (14,000~16,000 g) in a

1 microcentrifuge at 4 °C. The supernatant (cytosol fraction) was transferred into
2 a fresh pre-chilled 1.5 mL tube. Nuclear extraction buffer was added to the
3 pellets, and the tube was vortexed vigorously for 15 s, and then incubated on
4 ice for one min. The vortexing and incubation were repeated for 4 times. Then,
5 the nuclear extract was immediately transferred to a pre-chilled filter cartridge
6 with a collection tube and centrifuged at top speed in a microcentrifuge for 30 s.
7 The filter cartridge was discarded, and the nuclear extract was stored at -80 °C
8 until use.

9 **Primary culture of cardiac fibroblasts**

10 Neonatal mice were anesthetized with isoflurane (0.5%) in a gas chamber and
11 cleaned with 70% ethanol. Hearts were removed from mice, cut into small
12 pieces and put into spinning flasks (50~70 rpm) with D-Hank's digestive
13 solution (containing 0.0125% collagenase II) at 4 °C overnight. Then the
14 supernatant was discarded and a new D-Hank's digestive solution (containing
15 0.0125% pancreatin, without EDTA) was added to cover the tissues. The
16 flasks were incubated in the water bath at 37 °C at a low spinning speed for 2
17 min followed by pipetting up and down gently. The supernatant was collected
18 carefully and the same volume of Dulbecco's modified Eagle's medium
19 (DMEM; Gibco BRL, Gaithersburg, MD) containing 10% FBS was added to
20 stop the digestion. The new D-Hank's digestive solution (containing 0.0125%
21 pancreatin, without EDTA) was added to cover the rest tissues, and the
22 procedures were repeated until all tissues were digested. The pooled cells

1 were centrifuged for 5 min at 1,500 *g*, and the supernatant was discarded. Cell
2 pellets were resuspended using DMEM and centrifuged for 5 min at 1,500 *g*.
3 The supernatant was discarded, and the cells were plated in dishes in DMEM
4 and incubated at 37 °C in 5% CO₂. After cell culture for 1.5-2 h, cells adhered
5 to the dish were cardiac fibroblasts.

6